H.C. Wainwright raised the firm’s price target on Praxis Precision (PRAX) to $115 from $105 and keeps a Buy rating on the shares. The firm says the RADIANT trial data showcased vormatrigine’s “best-in-disease” efficacy in highly refractory focal onset seizure.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines Reports Promising Study Results
- Promising Potential of Praxis Precision Medicines: Buy Rating Affirmed by Douglas Tsao
- Praxis Announces Positive Results from RADIANT Study
- Praxis Precision reports Q2 EPS ($3.31), consensus ($3.36)
- Positive Phase 2 Results for Praxis Precision Medicines’ Vormatrigine Drive Buy Rating